PURPOSE: Functionally exhausted and mostly autoreactive B-cells with a peculiar CD21(low)CD11c(+) phenotype accumulate in several human immunological disorders including common variable immunodeficiency, HIV infection and rheumatoid arthritis. In HCV-associated mixed cryoglobulinemia (MC) there is accumulation of exhausted clonal B cells expressing a V(H)1-69-encoded cross-reactive idiotype; these cells are phenotypically heterogeneous, displaying either a CD21(low)CD11c(+) or a marginal zone (MZ)-like (IgM(+)CD27(+)CD21(+)CD11c(-)) phenotype. Irrespective of their phenotype, V(H)1-69(+) B-cells are unresponsive to the stimulation of Toll-like receptor 9 (TLR9). We investigated the fate of these cells after the eradication of HCV. METHODS: Fourteen MC patients were studied before and after antiviral therapy. V(H)1-69(+) B-cells were identified using the G6 monoclonal antibody and their phenotype and responsiveness to the stimulation of TLR9 were investigated. RESULTS: In seven virological non-responders, cryoglobulin levels and the number and phenotype of V(H)1-69(+) B cells remained substantially unchanged. By contrast, in sustained viral responders cryoglobulinemia subsided and the number of V(H)1-69(+) B cells declined. However, high proportions of MZ-like V(H)1-69(+) B cells retaining unresponsiveness to TLR9 stimulation persisted for several months in these patients. CONCLUSIONS: Clonal expansion of CD21(low) V(H)1-69(+) B cells may depend on continual stimulation by HCV, whereas their MZ-like counterparts may persist for years after the eradication of infection. Prolonged survival of exhausted MZ-like B cells after withdrawal of the initial inciting stimulus may contribute to the accumulation of autoreactive B cells in immunological disorders.
PURPOSE: Functionally exhausted and mostly autoreactive B-cells with a peculiar CD21(low)CD11c(+) phenotype accumulate in several humanimmunological disorders including common variable immunodeficiency, HIV infection and rheumatoid arthritis. In HCV-associated mixed cryoglobulinemia (MC) there is accumulation of exhausted clonal B cells expressing a V(H)1-69-encoded cross-reactive idiotype; these cells are phenotypically heterogeneous, displaying either a CD21(low)CD11c(+) or a marginal zone (MZ)-like (IgM(+)CD27(+)CD21(+)CD11c(-)) phenotype. Irrespective of their phenotype, V(H)1-69(+) B-cells are unresponsive to the stimulation of Toll-like receptor 9 (TLR9). We investigated the fate of these cells after the eradication of HCV. METHODS: Fourteen MC patients were studied before and after antiviral therapy. V(H)1-69(+) B-cells were identified using the G6 monoclonal antibody and their phenotype and responsiveness to the stimulation of TLR9 were investigated. RESULTS: In seven virological non-responders, cryoglobulin levels and the number and phenotype of V(H)1-69(+) B cells remained substantially unchanged. By contrast, in sustained viral responders cryoglobulinemia subsided and the number of V(H)1-69(+) B cells declined. However, high proportions of MZ-like V(H)1-69(+) B cells retaining unresponsiveness to TLR9 stimulation persisted for several months in these patients. CONCLUSIONS: Clonal expansion of CD21(low) V(H)1-69(+) B cells may depend on continual stimulation by HCV, whereas their MZ-like counterparts may persist for years after the eradication of infection. Prolonged survival of exhausted MZ-like B cells after withdrawal of the initial inciting stimulus may contribute to the accumulation of autoreactive B cells in immunological disorders.
Authors: Edgar D Charles; Claudia Brunetti; Svetlana Marukian; Kimberly D Ritola; Andrew H Talal; Kristen Marks; Ira M Jacobson; Charles M Rice; Lynn B Dustin Journal: Blood Date: 2011-03-18 Impact factor: 22.113
Authors: I R Rifkin; E A Leadbetter; B C Beaudette; C Kiani; M Monestier; M J Shlomchik; A Marshak-Rothstein Journal: J Immunol Date: 2000-08-01 Impact factor: 5.422
Authors: Mirzokhid Rakhmanov; Baerbel Keller; Sylvia Gutenberger; Christian Foerster; Manfred Hoenig; Gertjan Driessen; Mirjam van der Burg; Jacques J van Dongen; Elisabeth Wiech; Marcella Visentini; Isabella Quinti; Antje Prasse; Nadine Voelxen; Ulrich Salzer; Sigune Goldacker; Paul Fisch; Hermann Eibel; Klaus Schwarz; Hans-Hartmut Peter; Klaus Warnatz Journal: Proc Natl Acad Sci U S A Date: 2009-07-29 Impact factor: 11.205
Authors: Christina M Lau; Courtney Broughton; Abigail S Tabor; Shizuo Akira; Richard A Flavell; Mark J Mamula; Sean R Christensen; Mark J Shlomchik; Gregory A Viglianti; Ian R Rifkin; Ann Marshak-Rothstein Journal: J Exp Med Date: 2005-10-31 Impact factor: 14.307
Authors: James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts Journal: JCI Insight Date: 2017-04-20
Authors: Mazdak A Khalighi; Laith Al-Rabadi; Meghana Chalasani; Mark Smith; Siddhartha Kakani; Monica P Revelo; Shane M Meehan Journal: Kidney Int Rep Date: 2018-06-02